Results 191 to 200 of about 18,617,874 (263)

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Translational development of crisugabalin for neuropathic pain

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João   +5 more
wiley   +1 more source

Economic evaluations of antiobesity medications: A systematic literature review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković   +5 more
wiley   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich   +24 more
wiley   +1 more source

Rocavorexant, a novel, selective orexin‐1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Rocavorexant (INDV‐2000), a selective orexin‐1 receptor antagonist, reduces drug self‐administration and anxiety in nonclinical studies. This Phase 1 programme evaluated the safety, pharmacokinetics and pharmacodynamics of rocavorexant in healthy volunteers and treatment‐seeking individuals with opioid use disorder (OUD).
Martin Kankam   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy